Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ulrich Engelmann"'
Autor:
Seyed Mohammadali Dadfar, Denise Camozzi, Milita Darguzyte, Karolin Roemhild, Paola Varvarà, Josbert Metselaar, Srinivas Banala, Marcel Straub, Nihan Güvener, Ulrich Engelmann, Ioana Slabu, Miriam Buhl, Jan van Leusen, Paul Kögerler, Benita Hermanns-Sachweh, Volkmar Schulz, Fabian Kiessling, Twan Lammers
Publikováno v:
Journal of Nanobiotechnology, Vol 18, Iss 1, Pp 1-13 (2020)
Abstract Superparamagnetic iron oxide nanoparticles (SPION) are extensively used for magnetic resonance imaging (MRI) and magnetic particle imaging (MPI), as well as for magnetic fluid hyperthermia (MFH). We here describe a sequential centrifugation
Externí odkaz:
https://doaj.org/article/73e26f0efac04f6899a431bbd6eac73d
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtu
Externí odkaz:
https://doaj.org/article/d7fe2c76fdf646759d6a6c22a90eda35
Autor:
Boris A. Kallmann, Stefan Ries, Jennifer S. Kullmann, Laura M. Quint, Ulrich Engelmann, Andrew Chan
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background and aims: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. Methods: Prespecified analysis of a non-interventional, prospective, real-world stud
Externí odkaz:
https://doaj.org/article/3991bc1b2870421b89bfe667ff331ad1
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Background: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (MS). We aimed to obtain data on the effectiveness, tolerability, and subject satisfaction with teriflunomide
Externí odkaz:
https://doaj.org/article/05fbd0334c484b708b0d97440bad0417
Autor:
Ulrich Engelmann, Martin Baumann
In der Teamarbeit wird Moderation zum Erfolgsfaktor, der jedoch häufig unterschätzt wird. Ausgehend vom persönlichen Kompetenzniveau verknüpft dieses Buch Grundlagen und Methoden zu Wegen, um Ihre persönliche Entwicklung individuell zu begleiten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::740f5be15167f3486e0ff57b8e3bde1c
https://doi.org/10.36198/9783838556895
https://doi.org/10.36198/9783838556895
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Frontiers in Neurology
Frontiers in Neurology
The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtu
Autor:
Stefan Ries, Ulrich Engelmann, Jennifer S Kullmann, Boris Kallmann, Laura M Quint, Andrew T. Chan
Publikováno v:
Kallmann, Boris A; Ries, Stefan; Kullmann, Jennifer S; Quint, Laura M; Engelmann, Ulrich; Chan, Andrew (2021). Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status. Therapeutic advances in neurological disorders, 14, p. 17562864211005588. Sage 10.1177/17562864211005588
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disorders
Background and aims: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. Methods: Prespecified analysis of a non-interventional, prospective, real-world stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75354bdb730ef84846d2d7012b1034a2
https://boris.unibe.ch/157488/1/Kallmann__2021__Teriflunomide_in_relapsing_remitting_MS.pdf
https://boris.unibe.ch/157488/1/Kallmann__2021__Teriflunomide_in_relapsing_remitting_MS.pdf
Autor:
Ulrich Engelmann, Martin Baumann
In der Teamarbeit wird Moderation zum Erfolgsfaktor, der jedoch häufig unterschätzt wird. Ausgehend vom persönlichen Kompetenzniveau verknüpft dieses Buch Grundlagen und Methoden zu Wegen, um Ihre persönliche Entwicklung individuell zu begleiten
Autor:
Ulrich Engelmann
Die Stahlbaufibel stellt in übersichtlicher Form die Grundbausteine für die Konstruktion und Ausführung von Stabwerkskomponenten bereit. Zum besseren Verständnis sind die ausführlichen Beispiele mit Verweisen verknüpft (z. B. Nachweisabläufe).
Autor:
Raimar Kern, Ulrich Engelmann, Katja Thomas, Sigbert Jahn, Tjalf Ziemssen, Lina Hassoun, Alexandra Leptich
Publikováno v:
BMC Neurology
Background Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three